Lupin Ltd — Capital/Financing Update 2022

Nov 28, 2022

==> picture [79 x 93] intentionally omitted <==

November 28, 2022

 BSE Limited

Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

We are pleased to inform you that MedQuímica Indústria Farmacêutica, Brazil, wholly owned subsidiary of the Company, has signed Definitive Agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Rajvardhan Vishnu Satam

Digitally signed by Rajvardhan Vishnu Satam DN: c=IN, st=Maharashtra, 2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e 2abcf74700f5375b7, postalCode=400104, street=2404,SEJAL TOWER,SEJAL PARK,LINK ROAD,GOREGAON WEST,Mumbai,Motilal Nagar,Borivali,Mumbai Suburban, pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191, serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726 cdb67a2ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam Date: 2022.11.28 17:16:02 +05'30'

R. V. SATAM COMPANY SECRETARY (ACS - 11973)

Encl: a/a

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

Press Release

==> picture [66 x 69] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin's Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch Health

Mumbai, Sao Paulo, November 28, 2022 : Global pharma major, Lupin Limited (Lupin) announced today that its wholly owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica Ltda., a subsidiary of Bausch Health Companies Inc.

As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol™, Melleril™ and Dalmadorm™ for Central Nervous System related conditions, Bacrocin™, Glyquin™, Solaquin™, Oxipelle™ and Efurix™ as topical oncological treatments, and Cuprimine™ for the treatment of Wilson’s disease. This move reinforces our commitment to making healthcare solutions accessible to all patients.

“The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness,” said Alexandre Franca, Managing Director, MedQuímica. “This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market.”

About MedQuímica

MedQuímica Pharmaceutical Industries, with its factory located in the Industrial District of Juiz de Fora, has been operating for 47 years. In 2015 it became part of the Lupin Group, a global pharmaceutical company, and the fifth largest generics company in the United States by prescriptions and eighth largest company for generic medicine in the world. In Brazil, Medquímica develops an extensive line of both solid and liquid medicines classified into five lines: OTC (Over the counter medicines), Branded Generics, Hospital, Generics and Food Supplements.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Page 1 of 2

Press Release

==> picture [66 x 69] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Please visit www.lupin.com for more information.

Follow us on Twitter: https://twitter.com/LupinGlobal|LinkedIn: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications Email: shwetamunjal@lupin.com

Page 2 of 2